Aptabio Therapeutics (XKRX:293780) FCF Margin % : -234.29% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Aptabio Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aptabio Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was ₩-2,014 Mil. Aptabio Therapeutics's Revenue for the three months ended in Sep. 2024 was ₩859 Mil. Therefore, Aptabio Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was -234.29%.

As of today, Aptabio Therapeutics's current FCF Yield % is -9.89%.

The historical rank and industry rank for Aptabio Therapeutics's FCF Margin % or its related term are showing as below:

XKRX:293780' s FCF Margin % Range Over the Past 10 Years
Min: -16584.89 Med: -1718.78 Max: -122.17
Current: -547.8

During the past 7 years, the highest FCF Margin % of Aptabio Therapeutics was -122.17%. The lowest was -16584.89%. And the median was -1718.78%.

XKRX:293780's FCF Margin % is ranked worse than
95.37% of 993 companies
in the Drug Manufacturers industry
Industry Median: 0.89 vs XKRX:293780: -547.80

Aptabio Therapeutics FCF Margin % Historical Data

The historical data trend for Aptabio Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptabio Therapeutics FCF Margin % Chart

Aptabio Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-956.40

-1,718.78

-4,053.35

-16,584.89

-4,403.81

Aptabio Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-22,877.41	-2,724.27	-385.96	-318.50	-234.29

Competitive Comparison of Aptabio Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Aptabio Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptabio Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aptabio Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aptabio Therapeutics's FCF Margin % falls into.

Aptabio Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aptabio Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-14262.562	/	323.869
	=	-4,403.81 %

Aptabio Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-2013.529	/	859.408
	=	-234.29 %

Aptabio Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aptabio Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptabio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aptabio Therapeutics Inc (XKRX:293780) » Definitions » FCF Margin %

Traded in Other Exchanges

N/A

Address

13, Heungdeok 1-ro, Giheung-gu, Tower 504, Gyeonggi-do, Yongin-Si, KOR, 16954

Website

http://www.aptabio.com

Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.

Aptabio Therapeutics Headlines

No Headlines